GlycoMimetics
$3.929876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.05 (+1.30%) Today
+$0.03 (+0.77%) As of 11:49 AM UTC after-hours
Why Robinhood?
You can buy or sell GlycoMimetics and other stocks, options, and ETFs commission-free!
About GLYC
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD. The listed name for GLYC is GlycoMimetics, Inc. Common Stock.
CEO
Rachel K. King
Employees
57
Headquarters
Rockville, Maryland
Founded
2003
Market Cap
184.60M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
642.80K
High Today
$3.90
Low Today
$3.77
Open Price
$3.81
Volume
494.44K
52 Week High
$5.19
52 Week Low
$1.82
Collections
GLYC Earnings
-$0.39
-$0.26
-$0.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 26, Pre-Market